Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

First-in-class microbial ecosystem therapeutics 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumours (MET4-IO Trial)

ABSTRACT: First-in-class microbial ecosystem therapeutics 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumours (MET4-IO Trial)

PROVIDER: PRJNA819052 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

First-in-class microbial ecosystem therapeutics 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumours (MET4-IO Trial)

Project description:The intestinal microbiome has been associated with response to immune checkpoint inhibitors (ICI) in humans, and causally implicated in ICI responsiveness in animal models. Therapeutic augmentation of the microbiome in ICI recipients is being investigated in multiple ongoing human clinical trials. We conducted an early phase clinical trial of a cultivated, orally-delivered 30-species microbial consortium (microbial ecosystem therapeutic-4, MET4) designed for co-administration with ICIs and assessed safety, tolerability and ecological responses in patients with advanced solid tumors.

2022-03-26 | GSE199245 | GEO

RNAseq analysis of tumours from GEMMS animals to determine the effect of different aPDL1 combinations on lung tumours in situ

Project description:This study aims to identify combination treatments capable of inducing improved IO responses in lung tumours and thus, help guide decisions on the next combination arms for the HUDSON trial (post-IO). For that purpose, a lung tumour GEMM model was treated with either vehicle, PD-L1, ATR, ATR/PD-L1; Cisplatin/PD-L1/Ctla4 or VEGFR/PD-L1 and tumours collected for transcriptional profiling.

2024-01-29 | E-MTAB-13704 | biostudies-arrayexpress

Nymphalis io

Project description:Inachis io overview

| PRJNA693935 | ENA

CD137-CIS IO

Project description:CD137-CIS IO

| PRJNA663842 | ENA

Ia io

Project description:Ia io Genome sequencing and assembly

| PRJNA748544 | ENA

CREBBP is a novel tumour suppressor in solid tumours

Project description:The contribution of the majority of frequently mutated genes to tumourigenesis is not fully defined. Many aggressive human cancers, such as triple negative breast cancers (TNBCs), have a poor prognosis and lack tractable biomarkers and targeted therapeutic options. Here, we systematically characterize loss-of-function mutations to generate a functional map of novel driver genes in a 3-dimensional model of breast cancer heterogeneity that more readily recapitulates the unfavourable tumour microenvironment in vivo. This identified the histone acetyltransferase CREBBP as a potent tumour suppressor gene whose silencing provided a 3D-specific growth advantage only under oxygen and nutrient deplete conditions. CREBBP protein expression was altered in a substantial proportion of TNBCs as well as several other solid tumours, including endometrial, bladder, ovarian and squamous lung cancers. In multiple primary tumours and cell models, loss of CREBBP activity resulted in upregulation of the FOXM1 transcriptional network. Strikingly, treatment with a range of CDK4/6 inhibitors (CDK4/6i), that indirectly target FOXM1 activity, selectively impaired growth in both CREBBP-altered spheroids and cell line xenografts and patient derived models from multiple tumour types. This study is the first to provide rationale for CREBBP as a biomarker for CDK4/6i response in cancer representing a new treatment paradigm for tumours that harbour CREBBP alterations that have limited therapeutic options.

2022-03-23 | PXD012098 | Pride

Specific endothelical cells govern nanoparticle entry into solid tumours

Project description:We sequenced the transcroptome of isolated nanoparticle positive and nanoparticle negative tumour endothelial cells from mouse 4T1 mammary tumours

2021-09-07 | GSE172496 | GEO

Investigation of gene expression in IO-MEPL, ETMR and SHH-, Group 4-, as well as WNT-Medulloblastoma

Project description:The objective of this study was to investigate human IO-MEPL for SHH and WNT pathway activation.

2021-12-02 | GSE173763 | GEO

Acidithiobacillus ferridurans strain:IO-2C

Project description:Acidithiobacillus ferridurans strain:IO-2C Genome sequencing and assembly

| PRJNA432283 | ENA

KP lung tumours

Project description:KP lung tumours

| PRJNA577056 | ENA